



Timothy Elliott
Managing Director and Chief Regulatory Counsel
Legal Department

August 28, 2024

VIA ELECTRONIC PORTAL

Mr. Christopher J. Kirkpatrick
Office of the Secretariat
Commodity Futures Trading Commission
Three Lafayette Centre
1155 21st Street, N.W.
Washington, D.C. 20581

Re: FOIA Confidential Treatment Request

Dear Mr. Kirkpatrick:

By electronic portal dated today, August 28, 2024 the New York Mercantile Exchange Inc. ("NYMEX" or "Exchange") submitted a supplemental product certification filing (Submission No. 24-268S) to the Commodity Futures Trading Commission ("CFTC" or "Commission"). The supplemental filing includes an Appendix A and Appendix B for which the Exchange and Argus Media ("Argus") are submitting a detailed written justification setting forth grounds for this request for confidential treatment.

Pursuant to Sections 8 and 8(a) of the Commodity Exchange Act ("CEA"), as amended, and Commission Regulation 145.9(d), the Exchange requests confidential treatment of Appendix A and Appendix B on the grounds that disclosure of Appendix A and Appendix B would reveal confidential commercial information of the Exchange and of Argus. Pursuant to Commission Regulation 145.9(d)(5), the Exchange requests that confidential treatment be maintained for Appendix A and Appendix B until further notice from the Exchange. The Exchange also requests that the Commission notify the undersigned immediately after receiving any FOIA request for said Appendix A and Appendix B or any other court order, subpoena or summons for same. Finally, the Exchange requests notification in the event the Commission intends to disclose such Appendix A and Appendix B to Congress or to any other governmental agency or unit pursuant to Section 8 of the CEA. The Exchange does not waive its notification rights under Section 8(f) of the CEA with respect to any subpoena or summons for such Appendix A and Appendix B.

Should you have any questions concerning the above, please contact the undersigned at (312) 466-7478 or via e-mail at CMEGSubmissionInquiry@cmegroup.com.

Sincerely,

/s/ Timothy Elliott
Managing Director and Chief Regulatory Counsel

Attachment: Exhibit 1

Exhibit 1

DETAILED WRITTEN JUSTIFICATION



Timothy Elliott
Managing Director and Chief Regulatory Counsel
Legal Department

August 28, 2024

VIA ELECTRONIC PORTAL

Assistant Secretary of the Commission for FOIA,
Privacy and Sunshine Acts Compliance
Commodity Futures Trading Commission
Three Lafayette Centre, 8th Floor
1155 21st Street, N.W.
Washington, DC 20581

**Re: FOIA Confidential Treatment Request: Appendix A and Appendix B to NYMEX
Submission No. 24-268S**

Dear FOIA Compliance Staff:

I am writing on behalf of New York Mercantile Exchange Inc. ("NYMEX" or "Exchange") and Argus Media ("ARGUS"). In accordance with the requirements set forth in Commodity Futures Trading Commission ("CFTC" or "Commission") Regulation 40.8, the Exchange and ARGUS hereby submit their detailed written justification in support of continued confidentiality of the information set out in Appendix A and Appendix B to Submission No. 24-268S ("Appendix A and Appendix B") and respectfully requests that the Commission not release the information contained therein.

As discussed more fully below, Appendix A and Appendix B contain confidential and proprietary commercial information of the Exchange and ARGUS and is thus exempt from disclosure pursuant to Section 8 of the Commodity Exchange Act ("CEA"), Commission Regulation 145.9(d) and Exemption 4 (the "Exemption") to the Freedom of Information Act ("FOIA").

Presumption of Confidentiality

There is a presumption of confidentiality for commercial information that is (1) provided voluntarily and (2) is of a kind the provider would not customarily make available to the public. See Critical Mass Energy Project v. Nuclear Regulatory Commission, 975 F.2d 871, 878 (D.C. Cir. 1992) (en banc); see also Center for Auto Safety v. National Highway Traffic Safety Administration, 244 F.3d 144, 147 (D.C. Cir. 2001) (affirming continuing validity of Critical Mass and applying tests detailed in that case). The Exchange and ARGUS provided the confidential information in Appendix A and Appendix B to the Commission voluntarily in connection with the above referenced submission in order to demonstrate to the Commission the compliance with the CEA and relevant Commission Regulations. The information set out in Appendix A and Appendix B was developed by the Exchange and ARGUS at significant cost and over a substantial period of time. The Exchange would not customarily make such information available to the public. Disclosure of the confidential information in Appendix A and Appendix B would reveal confidential commercial information of ARGUS, which ARGUS licensed to the Exchange for a fee in connection with the development of the HVO FOB ARA Range (Class II) (Argus) Futures and HVO FOB ARA Range (Class II) (Argus) vs. Low Sulphur Gasoil Futures.

The terms of the license between ARGUS and the Exchange do not permit the Exchange to make the confidential information available to the public. ARGUS, which is in the business of gathering and providing information related to the biofuel markets, maintains the information as confidential and only discloses such information to persons who pay a license fee. The disclosure of the confidential information to the public would cause competitive harm to ARGUS by taking away its ability to collect license fees with respect to the confidential information and would cause competitive harm to the Exchange by limiting its ability to provide the cash market analysis needed for new product submissions.

Disclosure Would Likely Cause Competitive Harm to the Exchange and ARGUS

Notwithstanding this presumption of confidentiality, the confidential information in Appendix A and Appendix B still would be considered “confidential” because it is information that the Exchange and ARGUS would not and have not disclosed to the public and its disclosure would cause substantial and irreparable harm to the competitive position of the Exchange and ARGUS. FOIA was enacted to facilitate the disclosure of information to the public, but was clearly not intended to allow business competitors “cheap” access to valuable confidential information, especially when “competition in business turns on the relative costs and opportunities faced by members of the same industry.” Worthington Compressors v. Costle, 662 F.2d 45, 51 (D.C. Cir. 1981).

When a submitter of confidential information has a “commercial interest in the requested information the [E]xemption is properly invoked.” ISG Group, Inc. v. Dept. of Defense, 1989 WL 168858 (D.D.C. 1989). The test for determining confidentiality under the Exemption is set forth in National Parks & Conservation Association v. Morton, where the court held that information is confidential if its disclosure would “cause substantial harm to the competitive position of the person from whom the information was obtained.” In applying the “competitive harm” test for confidentiality, there is no requirement to demonstrate actual competitive harm. Gulf & Western Indus., Inc. v. United States, 615 F.2d 527, 530 (D.C. Cir. 1979). “Actual competition and the likelihood of substantial competitive injury is all that need to be shown.” Gulf & Western Indus., Inc. v. United States, 615 F.2d at 530. Information is confidential if: 1) there is actual competition in the relevant market; and 2) disclosure is likely to cause substantial competitive injury. Id. Neither the Commission nor the courts must conduct a sophisticated economic analysis to determine the likely effects of disclosure; evidence demonstrating the *potential* for economic harm is sufficient. Utah v. Bahe et al. No. 00-4018, 2001 WL 777034, at 2 (10th Cir. July 10, 2001); Public Citizen Health Research Group v. Food & Drug Admin., 704 F.2d 1280, 1291 (D.C. Cir. 1983).

The Exchange also satisfies the second requirement for the “competitive harm” test for confidentiality because the release of the information would likely cause substantial competitive injury to CME. See Gulf & Western Indus. Inc. v. United States 615 F.2d 527,530 (D.C. Cir. 1979). As noted above, a sophisticated economic analysis is unnecessary; the potential for economic harm is sufficient. Utah v. Bahe et al., No. 00-4018, 2001 WL 777034, at 2 (Cir. July 10, 2001); Public Citizen Health Research Group v. Food & Drug Admin., 704 F.2d 1280, 1291 (D.C. Cir. 1983).

Under circumstances similar to those involved here, courts have recognized that disclosure of commercial information holds the potential for significant competitive harm. Bahe No. 00-4018, 2001 WL 777034, at 2-3 (terms and structure of contract for storage of nuclear fuel confidential); Heeney v. Food & Drug Admin., 2001 U.S. App. Lexis 7732, at 3-4 (9th Cir. April 12, 2001) (manufacturing agreement and other information confidential); Professional Review Org. v. U.S. Department of Health and Human Servs., 607 F. Supp. 423, 425-26 (D.D.C. 1985) (business plans confidential). When applying the “substantial competitive harm test,” courts “[c]onsider how valuable the information will be to the requesting competitors and how much this gain will damage the submitter.” Worthington Compressors, 662 F.2d at 51. Since ARGUS sells this information to individuals for a fee pursuant to strict usage restrictions and it is not distributed publicly, making the confidential information public would clearly be valuable to ARGUS’ competitors and cause substantial damage to it.

Appendix A contains valuable commercial information with respect to pricing that was developed at significant cost and over a substantial period of time by ARGUS. It would destroy the value of that work if the Exchange was required to make that information available to the general public and/or ARGUS' competitors, who could free ride with no cost. Additionally, there is no regulatory imperative to disclose such information.

For the foregoing reasons, the Exchange and ARGUS respectfully request that the Commission maintain the confidential privilege afforded to this type of information and refrain from releasing Appendix A and Appendix B as such action could prove irreparably harmful.

Should you have any questions concerning the above, please contact the undersigned at (312) 466-7478 or via e-mail at CMEGSubmissionInquiry@cmegroup.com.

Sincerely,

/s/ Timothy Elliott
Managing Director and Chief Regulatory Counsel